Qualigen Therapeutics, Inc. Common Stock
Symbol: QLGN (NASDAQ)
4.23
▲ (7.63%) 0.300
Company Description:
Qualigen Therapeutics Inc is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's program, QN-302, is an investigational small-molecule G-quadruplexes (G4)-selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells.
Key Stats
- Today's Open: $3.925
- Today's High: $4.23
- Today's Low: $3.9
- Today's Volume: 2.92K
- Yesterday Close: $3.93
- Yesterday High: $4.06
- Yesterday Low: $3.64
- Yesterday Volume: 70.60K
- Last Min Volume: 330
- Last Min High: $4.23
- Last Min Low: $4.23
- Last Min VWAP: $4.23
Company Profile
- Name: Qualigen Therapeutics, Inc. Common Stock
- Website: https://www.qlgntx.com
- Listed Date: 2020-05-26
- Location: CALIFORNIA, CA
- Market Status: Active
- CIK Number: 0001460702
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $7.99M
- Round Lot: 100
- Outstanding Shares: 2.03M
- Asset Type: CS
RECENT FILINGS FOR QLGN
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-10-20 | DEF 14A | View |
| 2025-10-10 | PRE 14A | View |
| 2025-10-07 | 8-K | View |
| 2025-10-03 | 8-K | View |
| 2025-09-29 | 8-K | View |
| 2025-09-26 | EFFECT | View |
| 2025-09-25 | 8-K | View |
| 2025-09-24 | RW | View |
| 2025-09-16 | S-1 | View |
| 2025-09-16 | 8-K | View |
| 2025-09-08 | 8-K | View |
| 2025-08-27 | 8-K | View |
| 2025-08-14 | 10-Q | View |
| 2025-08-13 | D | View |
| 2025-08-07 | SCHEDULE 13G/A | View |
| 2025-07-28 | 8-K | View |
| 2025-07-28 | 8-K | View |
| 2025-07-21 | 10-Q | View |
| 2025-07-16 | 8-K | View |
| 2025-06-30 | 10-K | View |
Latest News on QLGN